Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_assertion type Assertion NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_head.
- NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_assertion description "[Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_provenance.
- NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_assertion evidence source_evidence_literature NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_provenance.
- NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_assertion SIO_000772 25480824 NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_provenance.
- NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_assertion wasDerivedFrom befree-2016 NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_provenance.
- NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_assertion wasGeneratedBy ECO_0000203 NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_provenance.